Intravacc is partnering with Wageningen Bioveterinary Research and Utrecht University to develop an intranasal COVID-19 vaccine.

The FDA approved Eli Lilly’s Baqsimi (glucagon) nasal powder 3 mg to treat severe hypoglycemia in diabetics 4 years of age and older.

Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.